Stenhouse Mark

Stenhouse Mark is listed in filings as Director at Phathom Pharmaceuticals, Inc.. This profile follows SEC Form 4 activity through May 21, 2026, including 3 public disclosures. Recent filings connect the profile to Phathom Pharmaceuticals, Inc. (PHAT). The current snapshot covers public activity from Jun 5, 2025 to May 21, 2026. Reported amounts are shown as $86.6K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.